Healwell AI Inc. (AIDX.TO)
| Previous Close | 1.4700 |
| Open | 1.4600 |
| Bid | 1.4700 x N/A |
| Ask | 1.5000 x N/A |
| Day's Range | 1.4300 - 1.4900 |
| 52 Week Range | 0.0850 - 1.9300 |
| Volume | |
| Avg. Volume | 863,636 |
| Market Cap | 214.228M |
| Beta (5Y Monthly) | -0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5600 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.34 |
GlobeNewswireHEALWELL AI Inc. Announces Upsize of Bought Deal to Up to $20 Million
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI INC. (“HEALWELL” or the “Company”) (TSX: AIDX) is pleased to announce today that, due to strong demand, it has agreed with Clarus Securities Inc. (“Clarus”) and Eight Capital Corp. (“Eight”), as Co-Bookrunners and Co-Lead Underwriters (the “Co-Lead Underwriters”), on behalf of a syndicate of underwriters (collectively, the “Underwriters”), to increa
- GlobeNewswire
HEALWELL AI Announces $16 Million Bought Deal Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. ("HEALWELL" or the "Company") (TSX: AIDX), a data science and AI company focused on preventative care, is pleased to announce that it has entered into an agreement pursuant to which Clarus Securities Inc. and Eight Capital, as lead underwriters and co-bookrunners, together with a syndicate of underwriters (collectively, the “Underwriters”), will pur
GlobeNewswireWELL Launches its Second-Generation AI powered Physician Co-pilot with Chronic Disease Detection Powered by HEALWELL AI
WELL and HEALWELL AI have launched the second-generation of WELL AI Decision Support (“WAIDS”), which now features advanced chronic disease screening for diseases like chronic kidney disease, hypertension, and diabetes, enabling patient risk stratification.The updated WAIDS tool identifies over one hundred diseases and delivers actionable clinical insights at the point of care, contributing to the management of chronic disease-related costs in Canada, which are estimated to be approximately $190
